You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
方盛製藥(603998.SH):2021年同田生物千金藤素的銷售收入僅為0.02萬元
格隆匯 05-17 18:12

格隆匯5月17日丨方盛製藥(603998.SH)發佈股票交易異常波動的公吿,公司近日關注到有媒體報道將公司列為千金藤素概念股,經核查,公司持股11.60%的參股子公司同田生物有千金藤素對照品生產銷售,其主營業務為高速逆流色譜儀(HSCCC)、高純度天然產物有效成分單體、天然藥物原料/中間體的研究開發、生產和銷售。千金藤素的銷售額佔同田生物的營業收入比重較小,2021年同田生物千金藤素的銷售收入僅為0.02萬元;2022年一季度千金藤素未產生銷售收入。除上述情況外,公司及其他子公司目前沒有千金藤素相關產品的研發、生產及銷售。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account